Zero-point plasma oscillations in Mn and its compounds

Goel, J.P.; Harsh, O.K.; Srivasta, K.S.

doi:10.1016/0378-4363(86)90224-x

Cited by 1 publication

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was previously demonstrated that NRP2 was upregulated in PCa upon PTEN loss and JNK/c-Jun activation. 13 In this reported cohort of 52 PCa patients, the expression of NRP2 was significantly associated with the invasive potential of PCa and lymph node or bone metastases whereby lymph node and bone metastases showed robust NRP2 expression. 13 These findings of Goel et al may be an explanation for the association of NRP2 with a shorter CSS especially in patients with unfavorable PCa.…”

Section: Discussionmentioning

confidence: 74%

“…13 In this reported cohort of 52 PCa patients, the expression of NRP2 was significantly associated with the invasive potential of PCa and lymph node or bone metastases whereby lymph node and bone metastases showed robust NRP2 expression. 13 These findings of Goel et al may be an explanation for the association of NRP2 with a shorter CSS especially in patients with unfavorable PCa. 13 However, the authors did not report any association of NRP2 expression with CSS.…”

Section: Discussionmentioning

confidence: 74%

“…13 These findings of Goel et al may be an explanation for the association of NRP2 with a shorter CSS especially in patients with unfavorable PCa. 13 However, the authors did not report any association of NRP2 expression with CSS. 13 We observed predominantly cytoplasmic staining of NRP2 in PCa cells, which was similar to our previous study in bladder cancer.…”

Section: Discussionmentioning

confidence: 85%

“…The finding that NRP2 regulates Bmi-1 and modulates IGF-1R signaling in PCa underscores its importance in PCa and as possible marker for treatment response for drugs targeting the IGF-1R pathway. 13 Moreover, calpain-mediated promoter methylation of the antimetastatic collapsing response mediator protein-4 (CRMP4) also promotes PCa metastases through the VEGFC/NRP2 axis. 29 Furthermore, it has already been shown that immunohistochemical staining of NRP1, the other member of the neuropilin family, in PCa tissues was associated with increased tumor stage and Gleason grading as well as with nodal status.…”

Section: Discussionmentioning

confidence: 99%

“…12 NRP2 also cross-talks with the insulin-like growth factor 1 receptor (IGF-1R) axis and promotes PCa progression and therapy resistance by regulating BMI-1 signaling. 13 Recently, the two most abundant isoforms of NRP2-NRP2a and NRP2b-have proven to elicit different functions in cancer cells. 7 In this respect, the hepatocyte growth factor (HGF) plays an important role for cancer progression by inducing NRP2bmediated Akt phosphorylation.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Neuropilin‐2 is an independent prognostic factor for shorter cancer‐specific survival in patients with acinar adenocarcinoma of the prostate

Borkowetz

Froehner

Rauner

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Neuropilin‐2 (NRP2) is a member of the neuropilin receptor family and known to regulate autophagy and mTORC2 signaling in prostate cancer (PCa). Our study investigated the association of immunohistochemical NRP2 expression with clinicopathological data in PCa patients. For this purpose, we generated a tissue microarray with prostate tissue specimens from 400 PCa patients treated by radical prostatectomy. We focused on patients with high‐risk factors such as extraprostatic extension (pT ≥ 3), Gleason score ≥8 and/or the presence of regional lymph node metastases (pN1). Protein levels of NRP2, the vascular endothelial growth factor C (VEGFC) and oncogenic v‐ets avian erythroblastosis virus E26 oncogene homolog (ERG) gene as an indicator for TMPRSS2‐ERG fusion was assessed in relation to the patients' outcome. NRP2 emerged as an independent prognostic factor for cancer‐specific survival (CSS) (hazard ratio 2.360, 95% confidence interval = 1.2–4.8; p = 0.016). Moreover, the association between NRP2 expression and shorter CSS was also especially pronounced in patients at high risk for progression (log‐rank test: p = 0.010). We evaluated the association between NRP2 and the TMPRSS2‐ERG gene fusion status assessed by immunohistochemical nuclear ERG staining. However, ERG staining alone did not show any prognostic significance. NRP2 immunostaining is significantly associated with shorter CSS in ERG‐negative tumors (log‐rank test: p = 0.012). No prognostic impact of NRP2 expression on CSS was observed in ERG‐positive tumors (log‐rank test: p = 0.153). Our study identifies NRP2 as an important prognostic marker for a worse clinical outcome especially in patients with a high‐risk PCa and in patients with ERG‐negative PCa.

show abstract

Section: Discussionmentioning

confidence: 74%